Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Inocras | Inocras Korea Inc.
Related tests:


Inocras and Watchmaker Genomics announce strategic collaboration in genomic innovation (Businesswire)
"Inocras...and Watchmaker Genomics...are thrilled to announce an expansion of their partnership to deliver solutions aimed at accelerating insights for patients and researchers...During development, Inocras rigorously tested several library preparation chemistries and ultimately selected the Watchmaker DNA Library Prep Kits with Fragmentation for its high library conversion efficiency, low-bias sequence coverage, and excellent sequence accuracy with challenging formalin-fixed, paraffin-embedded (FFPE) tissues."
Licensing / partnership
Inocras and Massive Bio forge groundbreaking alliance to revolutionize cancer care with whole-genome insights and clinical trial matching (Businesswire)
"Inocras...and Massive Bio...have joined forces to set a new standard for cancer patient care. This strategic collaboration leverages Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching, with the shared mission of enhancing personalized care for cancer patients."
Licensing / partnership
Inocras presents poster for breast cancer at 2024 ASCO Annual Meeting, showing transformative impact of WGS-based HRD testing (Businesswire)
"Inocras Inc...is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting...The study utilized a WGS-HRD approach to identify and validate radiomic features with predictive value for HRD, highlighting their potential as non-invasive imaging biomarkers for primary HRD screening."
Clinical data
Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S. (Businesswire)
"Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S. Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers....The partnership will focus on Inocras providing IMBdx’s liquid biopsy-based cancer diagnostics in the U.S. market, creating alternatives for patients and their providers when genetic testing from tissue biopsy is not feasible. This joint initiative introduces a new model of patient care, leveraging advanced two technologies in genetic testing - whole genome data and liquid biopsy."
Licensing / partnership
Getlabs and Inocras partner to create a seamless patient experience for cancer and rare disease testing (PRNewswire)
"Getlabs...has joined forces with Inocras...that empowers patients with critical genetic insights for cancer and rare diseases...Inocras provides whole genome sequencing tests, which deliver patients deep insights into their cancer and rare disease by providing comprehensive and detailed analyses of an individual's genetic composition."
Licensing / partnership
Inocras pioneers precision health with revolutionary whole genome insights (Businesswire)
"Inocras...proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively."
Inocras to Present Enhancing Genomic Analysis in Cancer Diagnostics at the 2024 AACR Annual Meeting (Businesswire)
"Inocras...is making an impact at the American Association for Cancer Research (AACR) 2024 annual meeting from April 5 to 10, held in San Diego. This event premieres Inocras's substantial research and pioneering innovation in cancer diagnostics, driven by cutting-edge machine learning technology...In their poster presentation, Inocras showcases the refined approach of machine learning in examining whole-genome sequencing (WGS) data from tissues preserved in formalin-fixed paraffin-embedded (FFPE) samples, a common preservation technique in clinical environments...The study unveils a cutting-edge machine learning strategy to accurately identify genetic changes caused by FFPE processing....this research sheds light on specific FFPE-induced genetic alteration patterns, such as cytosine deamination and unique mutational signatures, while proving its efficacy in assessing vital cancer and genomic metrics, including homologous recombination deficiency (HRD)..."
Clinical data